Last reviewed · How we verify
Free doxorubicin hydrochloride
Free doxorubicin hydrochloride is a anthracycline antibiotic Small molecule drug developed by Cephalon, Inc.. It is currently in Phase 2 development for Breast cancer, Ovarian cancer, Lung cancer. Also known as: Anthracycline.
Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death.
Doxorubicin hydrochloride intercalates DNA and inhibits topoisomerase II, leading to DNA damage and cell death. Used for Breast cancer, Ovarian cancer, Lung cancer.
At a glance
| Generic name | Free doxorubicin hydrochloride |
|---|---|
| Also known as | Anthracycline |
| Sponsor | Cephalon, Inc. |
| Drug class | anthracycline antibiotic |
| Target | DNA, Topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Doxorubicin hydrochloride functions by inserting itself between the base pairs of the DNA double helix (intercalation), which prevents DNA replication and transcription. Additionally, it inhibits topoisomerase II, an enzyme that helps manage the topology of DNA, causing double-strand breaks and further disrupting DNA function, ultimately leading to apoptosis.
Approved indications
- Breast cancer
- Ovarian cancer
- Lung cancer
- Leukemia
- Lymphoma
Common side effects
- Myelosuppression
- Cardiotoxicity
- Nausea and vomiting
Key clinical trials
- A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia (PHASE3)
- 6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors (PHASE2, PHASE3)
- Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer (PHASE2)
- Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer (PHASE2)
- Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (PHASE2)
- Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study (PHASE2)
- Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer (PHASE3)
- Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC） (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Free doxorubicin hydrochloride CI brief — competitive landscape report
- Free doxorubicin hydrochloride updates RSS · CI watch RSS
- Cephalon, Inc. portfolio CI
Frequently asked questions about Free doxorubicin hydrochloride
What is Free doxorubicin hydrochloride?
How does Free doxorubicin hydrochloride work?
What is Free doxorubicin hydrochloride used for?
Who makes Free doxorubicin hydrochloride?
Is Free doxorubicin hydrochloride also known as anything else?
What drug class is Free doxorubicin hydrochloride in?
What development phase is Free doxorubicin hydrochloride in?
What are the side effects of Free doxorubicin hydrochloride?
What does Free doxorubicin hydrochloride target?
Related
- Drug class: All anthracycline antibiotic drugs
- Target: All drugs targeting DNA, Topoisomerase II
- Manufacturer: Cephalon, Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Breast cancer
- Indication: Drugs for Ovarian cancer
- Indication: Drugs for Lung cancer
- Also known as: Anthracycline
- Compare: Free doxorubicin hydrochloride vs similar drugs
- Pricing: Free doxorubicin hydrochloride cost, discount & access